BioCentury | Sep 5, 2016
Company News

AstraZeneca, Pfizer deal

...Zinforo ceftaroline fosamil and Merrem /Meronem meropenam, as well as Phase II candidates, ATM-AVI and CXL...
...a combination of aztreonam and avibactam antibiotics, is in Phase II testing to treat cIAI. CXL...
BioCentury | Aug 24, 2016
Company News

Pfizer buying AZ's small molecule anti-infectives business

...to Merrem in certain Asian territories. The deal also gives Pfizer rights to ATM-AVI and CXL...
...testing. ATM-AVI combines antibiotics aztreonam and avibactam, and is in development to treat Gram-negative infections. CXL...
BioCentury | Nov 9, 2015
Company News

Cardioxyl, Bristol-Myers deal

...up to $1.8 billion in development, regulatory and sales milestones. Cardioxyl is developing lead candidate CXL-1427...
BioCentury | Nov 3, 2015
Company News

BMS acquires Cardioxyl

...acquire Cardioxyl Pharmaceuticals Inc. (Chapel Hill, N.C.), which is developing cardiovascular therapies including lead candidate CXL-1427...
BioCentury | Oct 8, 2015
Product R&D

Medicines Co.'s double play

...The Medicines Co. RPX7009 Meropenem Carbavance Gram-negative bacterial infections AstraZeneca plc Avibactam (NXL104) Ceftaroline fosamil CEF104...
BioCentury | Mar 3, 2014
Clinical News

CXL-1427: Phase I started

...U.S. Phase I trial to evaluate ascending doses of 24- and 48-hour infusions of IV CXL-1427...
...dose, in up to 110 healthy volunteers. Cardioxyl Pharmaceuticals Inc. , Chapel Hill, N.C. Product: CXL-1427...
BioCentury | Nov 9, 2012
Financial News

Cardioxyl raises $28.1M in B round

...investor Osage University and existing investors New Enterprise Associates and Aurora Funds also participated. Cardioxyl's CXL-1020...
BioCentury | Aug 30, 2010
Clinical News

CXL-1020: Phase IIa started

...to evaluate intravenous CXL-1020 in 54-66 patients. Cardioxyl Pharmaceuticals Inc. , Chapel Hill, N.C. Product: CXL-1020...
BioCentury | Aug 9, 2010
Clinical News

CXL-1020: Phase I/IIa data

...failure, IV CXL-1020 was well tolerated up to 10 µg/kg/minute with no serious adverse events. CXL-1020...
...activity in patients with relevant underlying disease. Cardioxyl Pharmaceuticals Inc. , Chapel Hill, N.C. Product: CXL-1020...
BioCentury | Aug 3, 2010
Financial News

Cardioxyl raises $15 million

...Aurora Funds and New Enterprise Associates co-led the round. Cardioxyl also said its lead compound, CXL-1020...
Items per page:
1 - 10 of 16